ATC Group: A07DA03 Loperamide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A07DA03 in the ATC hierarchy

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
10 mg

Active ingredients in A07DA03

Active Ingredient
Description

By binding to opiate receptors in the gut wall, loperamide hydrochloride reduces propulsive peristalsis, increases intestinal transit time and enhances resorption of water and electrolytes. Loperamide increases the tone of the anal sphincter, which helps reduce faecal incontinence and urgency.

Related product monographs

Title
Information Source
Document Type
 
Health Products Regulatory Authority (IE)
MPI, EU: SmPC
Υπουργείο Υγείας (CY)
MPI, EU: SmPC
Medicines & Healthcare Products Regulatory Agency (GB)
MPI, EU: SmPC
Υπουργείο Υγείας (CY)
MPI, EU: SmPC
Υπουργείο Υγείας (CY)
MPI, EU: SmPC

Medicines in this ATC group

Australia (AU)

Austria (AT)

Canada (CA)

Ecuador (EC)

Estonia (EE)

Finland (FI)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Malta (MT)

Mexico (MX)

Netherlands (NL)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.